2,550 reports of this reaction
3.4% of all CICLESONIDE reports
#4 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #4 most commonly reported adverse reaction for CICLESONIDE, manufactured by Covis Pharma US, Inc. There are 2,550 FDA adverse event reports linking CICLESONIDE to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 3.4% of all 74,022 adverse event reports for this drug.
Patients taking CICLESONIDE who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is moderately reported among CICLESONIDE users, representing a notable but not dominant share of adverse events.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for CICLESONIDE:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 2,550 FDA reports for CICLESONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 3.4% of all adverse event reports for CICLESONIDE, making it a notable side effect.
If you experience therapeutic product effect incomplete while taking CICLESONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.